Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1531 to 1545 of 2208 results for guidelines

  1. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

    Technology appraisal guidance
    Published
    26 September 2006

  2. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

    Technology appraisal guidance
    Published
    23 August 2006

  3. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

    Technology appraisal guidance
    Published
    27 September 2006

  4. Intrapartum care for healthy women and babies (CG190)

    This guideline has been updated and replaced by the NICE guideline on intrapartum care (NG235).

    Clinical guideline
    Published
    3 December 2014

  5. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    HealthTech guidance
    Published
    25 July 2011
    View recommendations

    Sections for HTG268

  6. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

    Antimicrobial prescribing guideline
    Published
    16 September 2019

  7. Pneumonia in adults: diagnosis and management (CG191)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

    Clinical guideline
    Last updated
    31 October 2023

  8. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Technology appraisal guidance
    Published
    23 July 2001

  9. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    5 June 2020

  10. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    15 January 2021

  11. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    20 January 2021

  12. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Technology appraisal guidance
    Published
    26 June 2001

  13. Depression in adults: recognition and management (CG90)

    This guideline has been updated and replaced by NICE guideline on depression in adults: treatment and management (NG222).

    Clinical guideline
    Published
    28 October 2009

  14. Head injury: assessment and early management (CG176)

    This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).

    Clinical guideline
    Last updated
    13 September 2019

  15. Pneumonia (community-acquired): antimicrobial prescribing (NG138)

    This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

    Antimicrobial prescribing guideline
    Published
    16 September 2019